Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,466 active trials11 approved drugs128 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00087685 | RAD001 in Recurrent Endometrial Cancer Patients | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07226427 |
| A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer |
| recruiting |
| Phase 1 |
| 100 |
| Stemline Therapeutics, Inc.INDUSTRY |
| 3 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07643012 | Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer(ADAPT-EC) | recruiting | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684846 | Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer(TLPPROC) | completed | N/A | 33 | University Medical Centre LjubljanaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04000880 | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health(AMPLIFY) | completed | N/A | 603 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study(INSPIRE) | not yet recruiting | N/A | 2,748 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07681414 | ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy | active not recruiting | — | 52 | Guizhou Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05429970 | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | recruiting | N/A | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06315257 | A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients | recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07186296 | EXoPERT EMERALD Clinical Study | recruiting | — | 1,400 | EXoPERTINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678047 | Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia | enrolling by invitation | N/A | 60 | Albert Einstein College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06291311 | Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants | recruiting | — | 50 | University Hospital TuebingenOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07125391 | Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer | recruiting | Phase 2 | 136 | Bai-Rong XiaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675733 | A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility(SHORTEN) | not yet recruiting | N/A | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07676370 | PROV-MESH: Prophylactic Ovarian Cancer MESH(PROV-MESH) | recruiting | N/A | 152 | Hospital Vall d'HebronOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03285152 | A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients | completed | N/A | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05401162 | Chemotherapy Supported by Autologous Hematopoietic Stem Cells | recruiting | N/A | 40 | Chongqing University Cancer HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05401175 | Hematopoietic Stem Cell-containing Autologous Blood Reinfusion for Bone Marrow Protection in Cervical Cancer Patients | recruiting | N/A | 40 | Chongqing University Cancer HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | recruiting | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07645625 | Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer(PROTECx) | recruiting | Phase 4 | 261 | University Medical Center GroningenOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673211 | Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer | not yet recruiting | — | 60 | Zhejiang Cancer HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer(Phase II) | not yet recruiting | Phase 2 | 49 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | not yet recruiting | — | 300 | Asan Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT03285230 | The French E3N Prospective Cohort Study(E3N) | active not recruiting | — | 100,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03326713 | Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project(GRACE) | completed | N/A | 668 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab(ASTEROID) | active not recruiting | Phase 1 | 61 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05691010 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | recruiting | Early Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 6, 2026source: clinicaltrials